These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 19329899

  • 1. Managing adverse events in the use of bevacizumab and chemotherapy.
    Blowers E, Hall K.
    Br J Nurs; ; 18(6):351-6, 358. PubMed ID: 19329899
    [Abstract] [Full Text] [Related]

  • 2. Adverse events in bevacizumab and chemotherapy: patient management.
    Blowers E, Hall K.
    Br J Nurs; ; 18(7):424-8. PubMed ID: 19373187
    [Abstract] [Full Text] [Related]

  • 3. Safety of bevacizumab in patients with metastatic breast cancer.
    Hamilton EP, Blackwell KL.
    Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
    [Abstract] [Full Text] [Related]

  • 4. Managing patients treated with bevacizumab combination therapy.
    Gordon MS, Cunningham D.
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [Abstract] [Full Text] [Related]

  • 5. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H, Saini S.
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [Abstract] [Full Text] [Related]

  • 6. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T, Lindley C.
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [Abstract] [Full Text] [Related]

  • 7. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, Investigators of the BRiTE study.
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [Abstract] [Full Text] [Related]

  • 8. Intricacies of bevacizumab-induced toxicities and their management.
    Gressett SM, Shah SR.
    Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
    [Abstract] [Full Text] [Related]

  • 9. Bevacizumab and ovarian cancer.
    Sato S, Itamochi H.
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
    Akun E, Okutur K, Seber S, Korkmaz T, Aydin K, Bozkurt M, Namal E, Hasbal B, Tecimer C, Demir G.
    J BUON; 2012 Feb; 17(4):669-76. PubMed ID: 23335523
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.
    Sanna G, Fabi A, Crivellari D, Saracchini S, Battelli N, Nisticò C, Capobianco AM, Zampa G, Bottini A, Del Prete S, Simoncini E, Galli A, Matasconi M, Restuccia E, Biganzoli L.
    Tumori; 2014 Feb; 100(4):432-8. PubMed ID: 25296593
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
    Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C.
    Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
    [Abstract] [Full Text] [Related]

  • 17. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D, Sartori S, Papi M, Drudi F, Castellani C, Carloni F, Tombesi P, Lazzari-Agli L.
    Oncology; 2011 Aug; 80(5-6):350-8. PubMed ID: 21791945
    [Abstract] [Full Text] [Related]

  • 18. Nursing considerations of bevacizumab use in multiple tumor types.
    Gobel BH.
    Oncol Nurs Forum; 2007 May; 34(3):693-701. PubMed ID: 17573328
    [Abstract] [Full Text] [Related]

  • 19. Understanding and managing the possible adverse effects associated with bevacizumab.
    Shord SS, Bressler LR, Tierney LA, Cuellar S, George A.
    Am J Health Syst Pharm; 2009 Jun 01; 66(11):999-1013. PubMed ID: 19451611
    [Abstract] [Full Text] [Related]

  • 20. Bevacizumab in the treatment of ovarian cancer.
    Han ES, Monk BJ.
    Expert Rev Anticancer Ther; 2007 Oct 01; 7(10):1339-45. PubMed ID: 17944559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.